Martin Faehling

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 696 citations

Interim Analysis, Surgical Oncology, Oncology +8

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study

Luca Valerio, Anna C. Mavromanoli, Stefano Barco et al. · European Heart Journal · 2022 · 163 citations · Full text

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

Essential role of calcium in vascular endothelial growth factor A‐induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole

Martin Faehling, Karl J. Föhr, Guido Fellbrich et al. · The FASEB Journal · 2002 · 124 citations

Calcium Signaling, Cellular Physiology, Tumor Biology +19

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni et al. · Annals of Oncology · 2021 · 105 citations · Full text

Oncology, Immune Checkpoint Inhibitor, Consolidation Nivolumab +6